Barclays raised the firm’s price target on AbbVie to $185 from $175 and keeps an Overweight rating on the shares post the Q4 report. The company reported a solid beat with surprise Skyrizi and Rinvoq outlooks, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABBV: